Categories: News

MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) — MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27th, 2022, at 12:00 pm ET.

Access to the live presentation is available at https://www.webcaster4.com/Webcast/Page/2828/44096

A replay will be available after the call on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact
MiNK Therapeutics 
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com 

 

Staff

Recent Posts

Digital Healthcare Market Size to reach $836.10 billion by 2031, growing at a CAGR of 21%, says Coherent Market Insights

BURLINGAME, Calif., July 4, 2024 /PRNewswire/ -- The global Digital Healthcare Market, valued at $220.10…

1 hour ago

Sectra publishes Annual Report and Sustainability Report for 2023/2024

LINKÖPING, Sweden , July 4, 2024 /PRNewswire/ -- Medical imaging IT and cybersecurity company Sectra (STO:…

1 hour ago

India-Based Dhiti Omics is Now Live on SOPHiA DDM™

The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and…

1 hour ago

Inogen Strengthens Leadership Team with Appointment of New General Counsel and Executive Vice President, Business Development

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for…

13 hours ago

Datasea Announces Closing of $2.25 Million Registered Direct Offering

BEIJING, July 3, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), a…

13 hours ago

Medical College of Wisconsin Set to Lead Key Initiative as Part of EDA Tech Hub Phase 2 Funding

MILWAUKEE, July 3, 2024 /PRNewswire/ -- The U.S. Economic Development Administration (EDA) has awarded $49…

13 hours ago